


STEREOCHEMISTRY ABSTRACTS

J.F.G.A. Jansen and B.L Feringa

Tetrahedron: Asymmetry 1992, 3, 581




1,3-diphenyl-penta-1-one

e.e. \leq 85% by HPLC analysis, chiracel OD
source of chirality: enantioselective 1,4-addition
absolute configuration 3R

N. Sakai, K. Nozaki, K. Mashima, and H. Takaya


Tetrahedron: Asymmetry 1992, 3, 583



E.e. = >99% [by HPLC analysis]
 $[\alpha]_D^{20} = -19.33$ (c 1.80, $CHCl_3$)
 Source of chirality: (*S*)-binaphthol
 Absolute configuration: S

N. Sakai, K. Nozaki, K. Mashima, and H. Takaya


Tetrahedron: Asymmetry 1992, 3, 583




E.e. = >99% [by HPLC analysis]
 $[\alpha]_D^{20} = -30.99$ (c 1.17, $CHCl_3$)
 Source of chirality: (*S*)-binaphthol
 Absolute configuration: S

N. Sakai, K. Nozaki, K. Mashima, and H. Takaya

Tetrahedron: Asymmetry 1992, 3, 583





E.e. = >99% [by HPLC analysis]
 $[\alpha]_D^{20} = +20.4$ (c 2.87, $CHCl_3$)
 Source of chirality: (*S*)-binaphthol
 Absolute configuration: S



E.e = >99% [by HPLC analysis]

 $[\alpha]_D^{20} = +43.39(c\ 1.09, \text{CHCl}_3)$ Source of chirality: (*R*)-binaphthol

Absolute configuration: R

(R)-(+)-N-(1-Hydroxybut-2-yl)
N-methylcinnamamide

mp. 75°C


 $[\alpha]_D +23.8 \quad (c\ 2, \text{PhH})$

Ee = 100%

Chiral source :

(R)-(-)-2-aminobutan-1-ol

Absolute configuration : R


(R)-(+)-N-(1-Benzyl-N-(1-benzyloxybut-2-yl)
N-methylcinnamamide $[\alpha]_D +80 \quad (c\ 2.8, \text{MeOH})$

Ee = 100%

Chiral source :

(R)-(-)-2-aminobutan-1-ol

Absolute configuration : R

(R)-(+)-N-Benzyl-N-(1-hydroxybut-2-yl)
cinnamamide

mp. 85.8°C



 $[\alpha]_D +10 \quad (c\ 5, \text{MeOH})$

Ee = 100%

Chiral source :



(R)-(-)-2-aminobutan-1-ol

Absolute configuration : R





(R)-(-)-3-Phenylpentanoic acid

$[\alpha]_D -46$ (c 4, PhH)
Ee = 92 %
Chiral source :
(R)-(-)-2-aminobutan-1-ol
Absolute configuration : R





(R)-(-)-3-Phenylheptanoic acid

$[\alpha]_{578} -37$ (c 8, PhH)
Ee = 100 %
Chiral source :
(R)-(-)-2-aminobutan-1-ol
Absolute configuration : R




(R)-(-)-3-Phenyl-4-methylpentanoic acid

$[\alpha]_D -31.8$ (c 3.8, PhH)
Ee = 78.5 %
Chiral source :
(R)-(-)-2-aminobutan-1-ol
Absolute configuration : R



(R)-(+)-N-Butyl-N-(1-hydroxybut-2-yl)cinnamamide

$[\alpha]_D +4$ (c 5, MeOH)
Ee = 100 %
Chiral source :
(R)-(-)-2-aminobutan-1-ol
Absolute configuration : R


C₂₁H₂₃ClFNO₂

1,1-Dimethylethyl 4-fluoro-N-[(4-chlorophenyl)-methylene]-α-methyl-D-phenylalaninate

E.e.=50% (by chiral HPLC)

Source of chirality: phase-transfer catalyst derived from cinchonine

Absolute configuration: R


C₂₁H₂₃Cl₂NO₂

1,1-Dimethylethyl 4-chloro-N-[(4-chlorophenyl)-methylene]-α-methyl-D-phenylalaninate

E.e.=48% (by chiral HPLC)

Source of chirality: phase-transfer catalyst derived from cinchonine

Absolute configuration: R


C₂₁H₂₃BrClNO₂

1,1-Dimethylethyl 4-bromo-N-[(4-chlorophenyl)-methylene]-α-methyl-D-phenylalaninate

E.e.=44% (by chiral HPLC)

Source of chirality: phase-transfer catalyst derived from cinchonine

Absolute configuration: R


C₂₁H₂₄ClNO₂

1,1-Dimethylethyl N-[(4-chlorophenyl)methylene]-α-methyl-D-phenylalaninate

E.e.=44% (by chiral HPLC)

Source of chirality: phase-transfer catalyst derived from cinchonine


Absolute configuration: R

 $C_{25}H_{26}ClNO_2$

E.e.=42% (by chiral HPLC)

Source of chirality: phase-transfer catalyst derived from cinchonine


Absolute configuration: R

 $C_{17}H_{22}ClNO_2$

E.e.=36% (by chiral HPLC)


Source of chirality: phase-transfer catalyst derived from cinchonine

Absolute configuration: R

 $C_{10}H_{12}ClNO_2$

E.e.>97% (by HPLC of diastereomeric GITC derivative)


Source of chirality: phase-transfer catalyst derived from cinchonine then crystallization of racemate

Absolute configuration: R
(assigned by HPLC of GITC derivative) $C_6H_8D_2O$ $[\alpha]^{25}_J = + 3.2 \text{ (c = 0.1, CHCl}_3\text{)}$

Absolute configuration : (2R, 3S) by NMR

Source of chirality : Microbiological reduction


(+)2,3-dideuteriocyclohexan-1-one

 $[\alpha]^{25}_J = +3.8 \quad (c = 0.12, CHCl_3)$

Absolute configuration : (2R, 3S) by NMR

Source of chirality : Microbiological reduction



(+)2,3,4,4,6,6-hexadeuteriocyclohexan-1-one

 $[\alpha]^{25}_J = -8 \quad (c = 0.2, CHCl_3)$

Absolute configuration : (2R, 3S) by NMR



Source of chirality : Microbiological reduction

(-)-2-methyl-3-deuteriocyclohexan-1-one

E.e. = >95 % (nmr of methylester in presence of tris[3-heptafluoropropylhydroxymethylene-
(+)-camphorato]europium(III)) $[\alpha]_D = -11 \quad (c 0.71, MeOH)$ Source of chirality : resolution with S-(-)- α -methylbenzylamine (5 crystall. from EtOAc)

Absolute configuration : R (assigned by rel.

X-ray of synthetic intermediate).




E.e. = >95 % (nmr /chiral shift reagent of synth. intermed.)

 $[\alpha]_{365} = -3 \quad (c 0.90, MeOH)$


Source of chirality : resolution of synth. intermed.

Absolute configuration : S (assigned by rel.


X-ray of synthetic intermediate).




E.e. = >95 % (nmr /chiral shift reagent of synth. intermed.)
 $[\alpha]_{365} = +20$ (c 1.41, MeOH)
 Source of chirality : resolution of synth. intermed.
 Absolute configuration : S (assigned by rel.
 X-ray of synthetic intermediate).




E.e. = >95 % (nmr /chiral shift reagent of synth. intermed.)
 $[\alpha]_D = +40$ (c 0.80, MeOH)
 Source of chirality : resolution of synth. intermed.
 Absolute configuration : S (assigned by rel.
 X-ray of synthetic intermediate).



E.e. = >95 % (nmr /chiral shift reagent of synth. intermed.)
 $[\alpha]_D = +32$ (c 0.92, MeOH)
 Source of chirality : resolution of synth. intermed.
 Absolute configuration : S (assigned by rel.
 X-ray of synthetic intermediate).



E.e. = >95 % (nmr /chiral shift reagent of synth. intermed.)
 $[\alpha]_D = +64$ (c 0.75, MeOH)
 Source of chirality : resolution of synth. intermed.
 Absolute configuration : S (assigned by rel.
 X-ray of synthetic intermediate).



N,N-di(-2-t-butyl-3-benzyloxypropyl)-N-methylamine

E.e. = >95 % (nmr /chiral shift reagent of synth.


intermed.)

 $[\alpha]_D = +75$ (c 0.42, MeOH)

Source of chirality : resolution of synth. intermed.

Absolute configuration : S,S (assigned by rel.

X-ray of synthetic intermediate).



N,N-di(-2-t-butyl-3-hydroxypropyl)-N-methylamine

E.e. = >95 % (nmr /chiral shift reagent of synth.


intermed.)

 $[\alpha]_D = +94$ (c 1.37, MeOH)

Source of chirality : resolution of synth. intermed.

Absolute configuration : S,S (assigned by X-ray of

corresponding ammonium S-(+)-10-camphorsulfonate salt).




dimethyl (S)-2,3-pentadienedioate

E.e. = 82.0% [by nmr with (+)-Eu(hfc)3]

Source of chirality: by complexation with Eu(hfc)3

Absolute configuration S

(assigned by comparison with calculated optical rotation)



(R)-6-Benzylaminocarbonylaminohexene


E.e.=100%

mp.: 56-57 °C


 $[\alpha]^{28}_D = -7.12$ (c 1.11, CH_2Cl_2)

Source of chirality: D-alanine


Absolute configuration: R




E.e.=100%
 $[\alpha]^{26}_D = -12.9$ (*c* 2.105, MeOH)
 Source of chirality: D-alanine
 Absolute configuration: 2*R*,6*R*




(2*R*,6*R*)-1-Benzyl-2-hydroxymethyl-6-methylpiperidine




E.e.=100%
 $[\alpha]^{24}_D = +77.3$ (*c* 1.125, CHCl₃)
 Source of chirality: D-alanine
 Absolute configuration: 2*R*,6*R*




Ethyl 3-[(2*R*,6*R*)-1-Benzyl-2-hydroxymethyl-6-methylpiperidinyl]-2-propenoate




E.e.=100%
 $[\alpha]^{26}_D = +39.4$ (*c* 1.985, CHCl₃)
 Source of chirality: D-alanine
 Absolute configuration: 2*R*,6*R*




3-[(2*R*,6*R*)-1-Benzyl-2-hydroxymethyl-6-methylpiperidinyl]-2-propenoate



E.e.=100%
 $[\alpha]^{25}_D = +43.4$ (*c* 1.625, CHCl₃)
 Source of chirality: D-alanine
 Absolute configuration: 2*R*,6*R*




(2*R*,6*R*)-1-Benzyl-2-[(methoxymethyl)oxy]-6-methyl-2-piperidinylpropan-1-ol



E.e.= >93%

 $[\alpha]^{25}_D = -9.8$ (*c* 1.2, EtOH)

Source of chirality: D-alanine


Absolute configuration: 2*R*,6*R*C₉H₁₇N(2*R*,6*R*)-6-methyl-2-(1-propenyl)piperidine

E.e.= >99%

mp.: 246-247 °C

 $[\alpha]^{26}_D = +12.7$ (*c* 1.0, EtOH)

Source of chirality: D-alanine

Absolute configuration: 2*S*,6*R*C₉H₂₀NCI(2*S*,6*R*)-6-methyl-2-propylpiperidineC₁₄H₁₇NO₃S

E.e. 100%


 $[\alpha]_D^{20} -72.9$ (*c* 1.68, CHCl₃)

Source of chirality: (S)-Phenylpropionic acid

Absolute configuration: 2*S*, SS

Use: Chiral dienophile for asymmetric Diels - Alder reaction

(2SS)-1-Nitro-2-(2-phenylpropylsulfinyl)cyclopentene

C₁₄H₁₇NO₃S

E.e. 100%



 $[\alpha]_D^{20} +388.3$ (*c* 0.84, CHCl₃)

Source of chirality: (S)-Phenylpropionic acid

Absolute configuration: 2*S*, SR

Use: Chiral dienophile for asymmetric Diels - Alder reaction

(2*S*,*S**R*)-1-Nitro-2-(2-phenylpropylsulfinyl)cyclopentene



(Z)-(2S,SS)-1-Nitro-2-(2-phenylpropylsulfinyl)-1-propene



E.e. 100%

[α]_D²⁰ -10.4 (c 0.72, CHCl₃)

Source of chirality: (S)-Phenylpropionic acid

Absolute configuration: 2S, SS

Use: Chiral dienophile for asymmetric Diels - Alder reaction





(1R,2R,6S,2'S,SS)-2-Methyl-1-nitro-6-(2'-phenylpropylsulfinyl)bicyclo[4.3.0]-3-nonene

D.e. 100%

[α]_D²² -211.3 (c 0.43, CHCl₃)

Source of chirality: Asymmetric Diels - Alder reaction under high pressure

Absolute configuration: 1R, 2R, 6S, 2'S, SS





(1R,6S,2'S,SS)-3,4-Dimethyl-1-nitro-6-(2'-phenylpropylsulfinyl)bicyclo[4.3.0]-3-nonene

D.e. 100%

[α]_D²⁰ -49.7 (c 1.27, CHCl₃)

Source of chirality: Asymmetric Diels - Alder reaction under high pressure

Absolute configuration: 1R, 6S, 2'S, SS




(1R,2R,6S,7S,2'S,SS)-2-Nitro-6-(2'-phenylpropylsulfinyl)tricyclo[5.2.1.0^{2,6}]-8-decene

D.e. 100%



[α]_D²⁰ -47.6 (c 0.79, CHCl₃)

Source of chirality: Asymmetric Diels - Alder reaction under high pressure



Absolute configuration: 1R, 2R, 6S, 7S, 2'S, SS




(1*S*,2*R*,6*S*,7*R*,2'*S*,*SS*)-2-Nitro-6-(2'-phenylpropylsulfinyl)tricyclo[5.2.1.0^{2.6}]-8-decene




(1*S*,6*R*,2'*S*,*SR*)-3,4-Dimethyl-1-nitro-6-(2'-phenylpropylsulfinyl)bicyclo[4.3.0]-3-nonene



(1*S*,2*S*,6*R*,7*R*,2'*S*,*SR*)-2-Nitro-6-(2'-phenylpropylsulfinyl)tricyclo[5.2.1.0^{2.6}]-8-decene



(1*R*,2*S*,6*R*,7*S*,2'*S*,*SR*)-2-Nitro-6-(2'-phenylpropylsulfinyl)tricyclo[5.2.1.0^{2.6}]-8-decene




D.e. 100%
 $[\alpha]_D^{20} -197.4 (c 0.57, \text{CHCl}_3)$

Source of chirality: Asymmetric Diels - Alder reaction under high pressure
 Absolute configuration: 1R, 2S, 6R, 2'S, SS




(1R,2S,6R,2'S,SS)-2,6-Dimethyl-1-nitro-2-(2'-phenylpropylsulfinyl)-4-cyclohexene




D.e. 100%
 $[\alpha]_D^{20} -84.2 (c 1.10, \text{CHCl}_3)$

Source of chirality: Asymmetric Diels - Alder reaction under high pressure
 Absolute configuration: 1R, 2S, 2'S, SS




(1R,2S,2'S,SS)-1-Nitro-2-(2'-phenylpropylsulfinyl)-2,4,5-trimethyl-4-cyclohexene




CD [(Δε (λ_{max})] = +0.89 (221)
 (MeCN)

Source of chirality: from natural cholesterol.
 Oxime-E/Z configuration from NMR and CD.
 $[\alpha]_D: +10.4 (\text{CHCl}_3, c=1.2)$



(6Z)-6-Hydroximino-5β-cholestane-3β-ol 3-acetate (1)




CD [(Δε (λ_{max})] = -5.53 (214), +3.0 (196)
 (MeCN)

Source of chirality: from natural cholesterol.
 Oxime-E/Z configuration from NMR and CD.
 $[\alpha]_D: -11.3 (\text{CHCl}_3, c=1.3)$



(6E)-6-Hydroximino-5β-cholestane-3β-ol 3-acetate (2)




CD[$(\Delta\epsilon(\lambda_{\max}))$] = -7.55(214), +12.8(196)
(MeCN)

Source of chirality: from natural cholesterol.
Oxime-E/Z configuration from NMR and CD.
[α]_D: +5.9(CHCl₃, c=1.8)

C₂₇H₄₇NO₂

(6E)-6-Hydroximino-5β-cholestane-5-ol (3)




CD[$(\Delta\epsilon(\lambda_{\max}))$] = -6.19(214), +13.4(195)
(MeCN)

Source of chirality: from natural cholesterol.
Oxime-E/Z configuration from NMR and CD.
[α]_D: +26.2(CHCl₃, c=1.3)

C₂₇H₄₇NO₃

(6E)-6-Hydroximino-5β-cholestane-3β,5-diol (4)




CD[$(\Delta\epsilon(\lambda_{\max}))$] = -6.54(215), +15.9(196)
(MeCN)

Source of chirality: from natural cholesterol.
Oxime-E/Z configuration from NMR and CD.
[α]_D: +21.9(CHCl₃, c=1.5)

C₂₇H₄₆BrNO₂

(6E)-6-Hydroximino-3β-bromo-5β-cholestane-5-ol (5)




CD[$(\Delta\epsilon(\lambda_{\max}))$] = -7.74(215), +17.7(196)
(MeCN)

Source of chirality: from natural cholesterol.
Oxime-E/Z configuration from NMR and CD.
[α]_D: +23.2(CHCl₃, c=1.3)


C₂₇H₄₆ClNO₂

(6E)-6-Hydroximino-3β-chloro-5β-cholestane-5-ol (6)




CD[$(\Delta\epsilon(\lambda_{\max}))$] = -6.12(215), +11.6(196)
(MeCN)

Source of chirality: from natural cholesterol.
Oxime-E/Z configuration from NMR and CD.
[α]_D: +7.4(CHCl₃, c=14.6)




(6E)-6-Hydroximino-5β-cholestane-3β,5-diol 3-acetate (7)




CD[$(\Delta\epsilon(\lambda_{\max}))$] = -7.07(214), +11.8(196)
(MeCN)

Source of chirality: from natural cholesterol.
Oxime-E/Z configuration from NMR and CD.
[α]_D: +1.8(CHCl₃, c=1.5)




(6E)-6-Hydroximino-5β-cholestane-3α,5-diol (8)




CD[$(\Delta\epsilon(\lambda_{\max}))$] = -7.92(214), +13.3(192)
(MeCN)

Source of chirality: from natural cholesterol.
Oxime-E/Z configuration from NMR and CD.
[α]_D: +17.4(CHCl₃, c=1.3)




(6E)-6-Hydroximino-5β-cholestane-3α,5-diol 3-acetate (9)




CD[$(\Delta\epsilon(\lambda_{\max}))$] = -6.52(219), +13.6(199)
(MeCN)

Source of chirality: from natural cholesterol.
Oxime-E/Z configuration from NMR and CD.
[α]_D: -0.7(CHCl₃, c=10.0)



(6E)-6-Acetoximino-5β-cholestane-3β,5-diol 3-acetate (10)




CD[$(\Delta\epsilon(\lambda_{\max})]$] = +1.30 (225)
(MeCN)

Source of chirality: from natural cholesterol.
Oxime-E/Z configuration from NMR and CD.
[α]_D: -34.3 (CHCl₃, c=11.4)

C₃₁H₅₁NO₅

(6E)-6-Hydroximino-5β-cholestane-3β,5-diol 3,5-diacetate (11)




CD[$(\Delta\epsilon(\lambda_{\max})]$] = +1.92 (228)
(MeCN)

Source of chirality: from natural cholesterol.
Oxime-E/Z configuration from NMR and CD.
[α]_D: -43.4 (CHCl₃, c=9.8)

C₃₃H₅₃NO₆

(6E)-6-Acetoximino-5β-cholestane-3β,5-diol 3,5-diacetate (12)




CD[$(\Delta\epsilon(\lambda_{\max})]$] = +1.04 (230)
(MeCN)

Source of chirality: from natural cholesterol.
Oxime-E/Z configuration from NMR and CD.
[α]_D: -52.0 (CHCl₃, c=1.1)

C₃₁H₅₁NO₅

(6E)-6-Hydroximino-5β-cholestane-3α,5-diol 3,5-diacetate (13)



E.e ≥ 98 % (by HPLC on Chiralcel OB column)

[α]_D²⁵ = + 176 (c = 0.010, acetone)


Source of chirality : microbiological oxidation of sulfide

C₉H₁₀OS

(E)-(S)-Methyl-(2-phenyl)
vinyl sulfide

Absolute configuration : S

(assigned by ¹H-NMR with reference to X-ray data).



E.e ≥ 98 % (by HPLC on Chiralcel OB column)


 $[\alpha]_D^{25} = + 157$ ($c = 0.012$, acetone)

Source of chirality : microbiological oxidation of sulfide

 $C_{10}H_{12}O_2S$

(E)-(S)-Methyl-[2-phenyl-(3'-methoxy)-yl] vinyl sulfoxide

Absolute configuration : S


(assigned by 1H -NMR with reference to X-ray data).E.e = 68 % (by 1H -NMR with Eu(hfc)₃)

Source of chirality : (-)-sulfonyl oxaziridine-based oxidation of sulfide

Absolute configuration : S

(assigned by 1H -NMR with reference to X-ray data). $C_{15}H_{14}OS$

Methyl-(2,2-diphenyl) vinyl sulfoxide



E.e ≥ 98 % (by HPLC on Chiralcel OB column)


 $[\alpha]_D^{25} = - 45$ ($c = 0.013$, acetone)

Source of chirality : microbiological oxidation of sulfide

 $C_{14}H_{13}NOS$

(Z)-(S)-Methyl-(2-phenyl-2-pyrid-4'-yl) vinyl sulfoxide

Absolute configuration : S

(assigned by 1H -NMR with reference to X-ray data of R enantiomer).


E.e = 72 % (by HPLC on Chiralcel OB column)

 $[\alpha]_D^{25} = - 25$ ($c = 0.050$, acetone)Source of chirality : (-)-diethyl tartrate/Ti(O-iPr)₄-based oxidation of sulfide $C_{14}H_{13}NOS$

(Z)-(S)-Methyl-(2-phenyl-2-pyrid-3'-yl) vinyl sulfoxide

Absolute configuration : S

(assigned by 1H -NMR with reference to X-ray data).




$C_{11}H_{13}NO_4$
p-Carboxymethylphenylphenylalanine

E.e. > 98% (based on chiral HPLC
of a precursor)

$[\alpha]_D^{25} = + 18.7$ (c1, H_2O)

Source of chirality : enantioselective
enzymatic hydrolysis of a precursor.
Absolute configuration 2R (D series).




$C_{11}H_{14}N_2O_4$
p-N-Hydroxycarboxamidomethylphenylphenylalanine

E.e. > 98% (based on chiral HPLC
of a precursor)

$[\alpha]_D^{25} = - 13.8$ (c1, H_2O)

Source of chirality : enantioselective
enzymatic hydrolysis of a precursor.
Absolute configuration 2S (L series).




$C_{10}H_{14}NO_5P$
p-Phosphonomethylphenylphenylalanine

E.e. > 98% (based on chiral HPLC
of a precursor)

$[\alpha]_D^{25} = + 11$ (c1, HCl 1N)

Source of chirality : enantioselective
enzymatic hydrolysis of a precursor.
Absolute configuration 2R (D series).




$C_{10}H_{12}NNaO_5S$
p-Sulfomethylphenylphenylalanine

E.e. > 98% (based on chiral HPLC
of a precursor)


$[\alpha]_D^{25} = + 15.8$ (c1, H_2O)

Source of chirality : enantioselective
enzymatic hydrolysis of a precursor.
Absolute configuration 2R (D series).




$[\alpha]_D = +42.1 (c=0.35, \text{CHCl}_3)$
CD [$\lambda_{\max} (\Delta\epsilon)$] (MeCN) : 297 (+2.81), 253 (+4.92), 225 (-1.1)
225 (-1.1), 213 (+4.2), 202 (-6.8)
Source of chirality: optically active precursor
Absolute configuration: S

$C_{17}H_{21}NO$
2,2-Dimethyl-3-phenyl-3-phenylamino-1-propanol




$[\alpha]_D = +51.5 (c=0.32, \text{CHCl}_3)$
CD [$\lambda_{\max} (\Delta\epsilon)$] (MeCN) : 299 (+3.00), 256 (+5.02), 226 (-1.1)
214 (+6.5), 203sh (-10.5), 190 (-83.7)
Source of chirality: optically active precursor
Absolute configuration: S

$C_{19}H_{23}NO$
3-Phenyl-3-phenylamino-2,2-tetramethylene-1-propanol




$[\alpha]_D = +47.3 (c=0.22, \text{CHCl}_3)$
CD [$\lambda_{\max} (\Delta\epsilon)$] (MeCN) : 299 (+2.53), 257 (-5.20), 226 (-1.2)
214 (+8.0), 204sh (-8.8), 192 (-65)
Source of chirality: optically active precursor
Absolute configuration: S

$C_{20}H_{25}NO$
2,2-Pentamethylene-3-phenyl-3-phenylamino-1-propanol



$[\alpha]_D = -51.1 (c=0.68, \text{CHCl}_3)$
CD [$\lambda_{\max} (\Delta\epsilon)$] (MeCN) : 294 (+3.30), 249 (+5.47), 222 (-2.1),
213 (+4.1), 202 (-6.5)
Source of chirality: asymm. synthesis with natural menthol
as a starting material
Absolute configuration: 3S from X-Ray

$C_{27}H_{37}NO_2$
(-)-Menthyl-2,2-dimethyl-3-phenyl-3-phenylaminopropanoate




$[\alpha]_D = -52.1$ ($c=0.19, \text{CHCl}_3$)


CD [$\lambda_{\max}(\Delta\epsilon)$] (MeCN) : 295 (+2.94), 249 (+5.52), 223 (-2.2),
213 (+4.2), 201sh (-13.4), 190 (-84)

Source of chirality: asymm. synthesis with natural menthol
as a starting material

Absolute configuration: 3S



(-) -Menthyl-3-phenylamino-2,2-tetramethylenepropanoate




$[\alpha]_D = -66.6$ ($c=0.22, \text{CHCl}_3$)


CD [$\lambda_{\max}(\Delta\epsilon)$] (MeCN) : 296 (+3.31), 269 (-0.44), 250 (+4.9),
224 (-2.7), 215 (+6.1), 202sh (-15.7),
191 (-80)

Source of chirality: asymm. synthesis with natural menthol
as a starting material

Absolute configuration: 3S



(-) -Menthyl-2,2-pentamethylene-3-phenyl-3-phenylaminopropanoate




$[\alpha]_D = +234.0$ ($c=0.27, \text{CHCl}_3$)


CD [$\lambda_{\max}(\Delta\epsilon)$] (MeCN) : 295sh (+0.50), 274sh (+0.68), 252 (+6.7),
217 (+3.7), 202 (-1.2), 197 (+2), negative
at shorter wavelengths

Source of chirality: optically active precursor

Absolute configuration: S



3,3-Dimethyl-1,4-diphenylazetididine




$[\alpha]_D = +157.0$ ($c=0.29, \text{CHCl}_3$)


CD [$\lambda_{\max}(\Delta\epsilon)$] (MeCN) : 290sh (+0.71), 252 (+8.2), 217 (+5.9),
204 (-7.1), 195 (+19), negative at shorter
wavelengths

Source of chirality: optically active precursor

Absolute configuration: S



3,3-Dimethyl-1,4-diphenyl-2-azetidinone



$[\alpha]_D = +182.0$ ($c=0.20, \text{CHCl}_3$)


CD [$\lambda_{\max}(\Delta\epsilon)$] (MeCN): 282 (-0.44), 277sh (-0.28), 268sh (+1.52),
245 (+9.7), 223sh (+2.9), 209 (-4.9),
199 (+2.0), 192 (-11)

Source of chirality: optically active precursor

Absolute configuration: S

C₁₉H₂₁N

1,2-Diphenyl-2-azaspiro [3,4] octane



$[\alpha]_D = +120.0$ ($c=0.27, \text{CHCl}_3$)


CD [$\lambda_{\max}(\Delta\epsilon)$] (MeCN): 284 (-0.29), 270sh (+2.68), 245 (+11.5),
209 (-7.1), 191 (-47)

Source of chirality: optically active precursor

Absolute configuration: S

C₁₉H₁₉NO

2,3-Diphenyl-2-azaspiro [3,4] octane-1-one



$[\alpha]_D = +119.7$ ($c=0.15, \text{CHCl}_3$)


CD [$\lambda_{\max}(\Delta\epsilon)$] (MeCN): 284 (-0.26), 269sh (+1.89), 245 (+11.0),
210 (-10.8), 192 (-50)

Source of chirality: optically active precursor

Absolute configuration: S

C₂₀H₂₁NO

2,3-Diphenyl-2-azaspiro [3,4] nonane-1-one



$[\alpha]_D = -172.0$ ($c=0.25, \text{CHCl}_3$)


CD [$\lambda_{\max}(\Delta\epsilon)$] (MeCN): 291 (+0.17), 248 (-11.9), 222 (+2.9),
209sh (-13.2), 197 (-30)

Source of chirality: optically active precursor

Absolute configuration: S

C₁₈H₂₁NO

5,5-Dimethyl-3,4-diphenyl-tetrahydro-1,3-oxazine




$[\alpha]_D = -6.8$ ($c=0.20, \text{CHCl}_3$)

CD [$\lambda_{\max}(\Delta\epsilon)$] (MeCN) : 300sh(+2.13), 288(+3.32), 273sh(-4.90),
245(-9.9), 213sh(-24.7),
196(-117), positive at shorter
wavelengths

Source of chirality: optically active precursor
Absolute configuration: S

C₂₀H₂₃NO

9,10-Diphenyl-7,9-oxazaspiro [4,5] decane




$[\alpha]_D = -86.4$ ($c=0.28, \text{CHCl}_3$)

CD [$\lambda_{\max}(\Delta\epsilon)$] (MeCN) : 300sh(+0.32), 291(+0.36), 268sh(-2.10),
244(-9.1), 209sh(-17.5), 196(-63)

Source of chirality: optically active precursor
Absolute configuration: S

C₂₁H₂₅NO

4,5-Diphenyl-2,4-oxazaspiro [5,5] undecane




$[\alpha]_D = +38.5$ ($c=0.21, \text{CHCl}_3$)

CD [$\lambda_{\max}(\Delta\epsilon)$] (MeCN) : 272(-0.29), 265(+0.17), 260(-0.14),
226(-8.2), 222sh(-7.8), 213(-8.1),
194(+7), negative at shorter wavelengths

Source of chirality: optically active precursor
Absolute configuration: S

C₁₈H₁₉NO₂

5,5-Dimethyl-3,4-diphenyl-tetrahydro-1,3-oxazine-2-one




$[\alpha]_D = +6.4$ ($c=0.15, \text{CHCl}_3$)

CD [$\lambda_{\max}(\Delta\epsilon)$] (MeCN) : 273(+0.37), 265(+0.23), 261(-0.18),
227(-12.2), 214(-13.2), 192(+109),
negative at shorter wavelengths

Source of chirality: optically active precursor
Absolute configuration: S

C₂₀H₂₁NO₂

9,10-Diphenyl-7,9-oxazaspiro [4,5] decane-8-one



$[\alpha]_D = -15.1$ ($c=0.22, \text{CHCl}_3$)

CD [$\lambda_{\max}(\Delta\epsilon)$] (MeCN): 273 (+0.34), 266 (+0.22), 261 (-0.15),
227 (-10.8), 214 (-10.6), 191 (+103),
negative at shorter wavelengths

Source of chirality: optically active precursor

Absolute configuration: S

C₂₁H₂₃NO₂

4,5-Diphenyl-2,4-oxazaspiro [5,5] undecane-3-one